Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.

[1]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[2]  P P Chamberlain,et al.  Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. , 2004, Journal of molecular biology.

[3]  Jan Balzarini,et al.  In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[4]  G. Weverling,et al.  TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen , 2003, AIDS.

[5]  Olson Wc,et al.  Resistance to HIV-1 entry inhibitors. , 2003 .

[6]  Alexey Yakovlev,et al.  A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects , 2003, AIDS.

[7]  W. L. Jorgensen,et al.  Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. , 2003, Bioorganic & medicinal chemistry letters.

[8]  F. Belardelli,et al.  Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation , 2003, AIDS.

[9]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[10]  Julian Tirado-Rives,et al.  Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. , 2003, Journal of the American Chemical Society.

[11]  Eddy Arnold,et al.  On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data , 2003, J. Comput. Aided Mol. Des..

[12]  Thomas Klimkait,et al.  Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. , 2002, Journal of molecular biology.

[13]  Erik De Clercq,et al.  New anti‐HIV agents and targets , 2002, Medicinal research reviews.

[14]  A. Velázquez‐Campoy,et al.  Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.

[15]  Jon Cohen.  Raising the Limits , 2002, Science.

[16]  E. De Clercq,et al.  Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. , 2002, AIDS research and human retroviruses.

[17]  E. Clercq,et al.  Highlights in the development of new antiviral agents. , 2002 .

[18]  S. Sigurdsson,et al.  Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. , 2002, European journal of biochemistry.

[19]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) , 2001 .

[20]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[21]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[22]  A. D. Clark,et al.  The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. , 2001, Journal of molecular biology.

[23]  A. D. Clark,et al.  Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.

[24]  M. Peeters,et al.  Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. , 2001 .

[25]  D I Stuart,et al.  Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.

[26]  Jan Balzarini,et al.  Phenylethylthiazolylthiourea (PETT) Non-nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases , 2000, The Journal of Biological Chemistry.

[27]  Oberg,et al.  Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues , 1999, Journal of medicinal chemistry.

[28]  A. D. Clark,et al.  Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Sarafianos,et al.  Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. , 1999, Chemistry & biology.

[30]  A. D. Clark,et al.  Sarafianos, S.G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with -branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027-10032 , 1999 .

[31]  A. D. Clark,et al.  Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. , 1998, Journal of molecular biology.

[32]  A. D. Clark,et al.  Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. , 1998, Journal of molecular biology.

[33]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[34]  D I Stuart,et al.  Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.

[35]  A T Brünger,et al.  Recent developments for the efficient crystallographic refinement of macromolecular structures. , 1998, Current opinion in structural biology.

[36]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[37]  D I Stuart,et al.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Stephenson.  The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatments. , 1997, JAMA.

[39]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[40]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[41]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[42]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[43]  R. Goody,et al.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[45]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .

[46]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[47]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[48]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[49]  D W Rodgers,et al.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[51]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[52]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[53]  E. De Clercq,et al.  New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs , 1994, Antimicrobial Agents and Chemotherapy.

[54]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[55]  B. Larder,et al.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.

[56]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Pauwels,et al.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[59]  A. Bacolla,et al.  Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[61]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.